Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06021795 · ClinicalTrials.gov registry record · NA
Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia
A NA study, sponsored by Third Wave Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT06021795: Completed NA study, sponsored by Third Wave Therapeutics.
NCT06021795 is a NA study that has completed, run by Third Wave Therapeutics. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06021795, a NA study, has completed, sponsored by Third Wave Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Assess the effect of a customized audio track delivered via standard commercially-available bone conduction headsets on the quality of sleep
Primary Outcome
Reduction in Insomnia Severity
Interventions
- DEVICE Sound Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
What the finished NCT06021795 record still lists
NCT06021795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Sound Treatment is the first listed.
NCT06021795 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06021795 about?
NCT06021795 is a clinical study titled "Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia". Assess the effect of a customized audio track delivered via standard commercially-available bone conduction headsets on the quality of sleep
What is the current status of trial NCT06021795?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2023-07-01. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT06021795?
The interventions under investigation include: Sound Treatment (DEVICE).
Who is sponsoring clinical trial NCT06021795?
This trial is sponsored by Third Wave Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06021795's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI